Intellia Therapeutics, Inc. - 8-K Filing

Intellia Therapeutics reports Q3 2026 net loss of $127.5 million and announces $400 million term loan facility with OrbiMed. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR · November 5, 2026, 13:15 UTC

Tickers: $NTLA

Read the full article at SEC EDGAR

More Regulatory news

Cohen & Co Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:48 UTC
UNITED BANCORP INC /OH/ - 10-Q Filing SEC EDGAR · November 12, 2026, 15:33 UTC
PATRIOT GOLD CORP - 10-Q Filing SEC EDGAR · November 12, 2026, 15:32 UTC
First Digital Acquisition Corp Ltd. - 8-K Filing SEC EDGAR · November 12, 2026, 15:29 UTC
GROOVE BOTANICALS INC. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:24 UTC
Johnson Controls International plc - 10-K Filing SEC EDGAR · November 12, 2026, 15:24 UTC
OLD NATIONAL BANCORP /IN/ - 8-K Filing SEC EDGAR · November 12, 2026, 15:20 UTC
AMTECH SYSTEMS INC - 8-K Filing SEC EDGAR · November 12, 2026, 15:16 UTC
REGIONAL HEALTH PROPERTIES, INC - 8-K Filing SEC EDGAR · November 12, 2026, 15:09 UTC
Bitwise Avalanche ETF - 8-K Filing SEC EDGAR · November 12, 2026, 15:06 UTC